Trials / Recruiting
RecruitingNCT06007924
A Study of Avutometinib and Defactinib in People With Thyroid Cancer
Phase II of Avutometinib (VS-6766) and Defactinib In RAF Dimer-Driven RAI-Refractory Differentiated and Anaplastic Thyroid Cancer Patients
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The researchers are doing this study to find out if the combination of avutometinib and defactinib is an effective treatment for RAF dimer-driven radioiodine-refractory differentiated thyroid cancer or anaplastic thyroid cancer. The researchers will also test whether avutometinib and defactinib is a safe treatment that causes few or mild side effects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Avutometinib | Avutometinib 3.2 mg twice weekly 3 weeks on/1 week off |
| DRUG | Defactinib | Defactinib 200 mg twice daily 3 weeks on/1 week off |
Timeline
- Start date
- 2023-08-16
- Primary completion
- 2027-08-16
- Completion
- 2027-08-16
- First posted
- 2023-08-23
- Last updated
- 2026-03-27
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06007924. Inclusion in this directory is not an endorsement.